IP Library Granted Patent US 12,544,527
Granted Patent B2
US 12,544,527 · App. 18/310,152 · Granted Feb 10, 2026

Start-up protocols for nitric oxide delivery device

Inventors: David H. Fine (Cocoa Beach, FL); Edward Bromberg (Orlando, FL); Ryan Denton (Titusville, FL); Jason White (Cocoa, FL); Lucas G. Gamero (Oviedo, FL); Bryan Johnson (Orlando, FL); Gregory Vasquez (Cocoa, FL); Doug Sonosky (Cocoa, FL)
Assignee: VERO Biotech Inc.
A61M16/122A61M16/0057A61M16/0666A61M2016/1025A61M2202/0208A61M2202/0275A61M2205/15A61M2205/3368A61M2205/6018
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,544,527
App. No.
18/310,152
Granted
Feb 10, 2026
Kind
B2
Abstract

Start-up protocols for a device and method for administering NO is described.

Claims (24)

1 . A system, comprising:

a delivery line;

a source of NO 2 gas;

a device converting the NO 2 gas to an NO gas in a predetermined amount, wherein the NO gas is then supplied to the delivery line;

a first source of air and/or oxygen and a second source of air and/or oxygen, wherein the second source is a back-up source and wherein the first and the second sources of air and/or oxygen uninterruptedly supply air and/or oxygen,

a first pump, connected to the first source, which supplies air and/or oxygen from the first source to the delivery line;

a second pump, wherein the second pump is a back-up pump that is connected to the second source and that supplies air and/or oxygen from the second source to the delivery line, wherein the second pump is only used in conditions comprising failure of the first pump, flushing of the system, providing a NO gas flow dilution, or a combination thereof; and

wherein the first pump comprises check valves preventing air and/or oxygen from the second pump from entering the first pump.

2 . The system of claim 1 , wherein the source of NO 2 gas is a liquid N 2 O 4 .

3 . The system of claim 2 , wherein NO 2 gas is formed by heating of the liquid N 2 O 4 .

4 . The system of claim 1 , further comprising a leak detector.

5 . The system of claim 4 , wherein the leak detector automatically assesses the system for leaks.

6 . The system of claim 1 , wherein the system further comprises a filter configured to substantially remove dirt and/or dust particles from the source of air and/or oxygen.

7 . The system of claim 1 , wherein the system further comprises a moisture exchanger.

8 . The system of claim 2 , wherein in the last 30 min the liquid N 2 O 4 is depleted, and the NO is formed from a hot and pressured NO 2 /N 2 O 4 vapor.

9 . The system of claim 1 , further comprising a feedback loop, wherein the feedback loop controls a temperature increase to maintain the predetermined amount of NO.

10 . The system of claim 1 , wherein the controller is configured to detect the first pump failure, shut the first pump, and turn the second pump on for uninterrupted delivery of air and/or oxygen.

11 . The system of claim 1 , wherein the system further comprises a first NO sensor and a second NO sensor, wherein the first and the second NO sensors are independent of each other.

12 . The system of claim 1 , wherein the system further comprises a NO 2 sensor positioned in the delivery line.

13 . The system of claim 1 , wherein the system further comprises an O 2 sensor.

14 . The system of claim 1 , further comprising a controller determining the remaining NO gas supply based on a temperature and/or time interval at the temperature needed to maintain the predetermined amount of NO and providing an alert when up to 30 min of the NO gas supply is left in the system.

15 . The system of claim 4 , wherein the leak detector comprises a monitor of voltage drawn by valves in the device.

16 . The system of claim 1 , wherein the first pump is set to operate above stall conditions.

17 . The system of claim 1 , wherein the device comprises a volume accumulator and a restrictor configured to minimize pressure pulses of the first pump and/or the second pump.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Mar 18, 2026
From: HORIZON TECHNOLOGY FINANCE CORPORATION
To: VERO BIOTECH INC.
Reel/Frame 075308/0198 →
SECURITY INTEREST Recorded Mar 16, 2026
From: VERO BIOTECH INC.
To: SYMBIOTIC CAPITAL AGENCY LLC, AS COLLATERAL AGENT
Reel/Frame 075117/0935 →
SECURITY INTEREST Recorded Jan 3, 2024
From: VERO BIOTECH INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 066187/0865 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2023
From: FINE, DAVID H.
To: VERO BIOTECH LLC
Reel/Frame 065437/0524 →
CHANGE OF NAME Recorded Nov 2, 2023
From: VERO BIOTECH LLC
To: VERO BIOTECH INC.
Reel/Frame 065445/0524 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2023
From: BROMBERG, EDWARD; DENTON, RYAN; WHITE, JASON; GAMERO, LUCAS G.; JOHNSON, BRYAN; VASQUEZ, GREGORY; SONOSKY, DOUG
To: GENO LLC
Reel/Frame 065445/0233 →
CHANGE OF NAME Recorded Nov 2, 2023
From: GENO LLC
To: VERO BIOTECH LLC
Reel/Frame 065445/0521 →
Continuity (3)
Continuation 16513312 · Jul 16, 2019
Provisional Application 62699791 · Jul 18, 2018
Related Publication 20230414896A1 · Dec 28, 2023
References Cited (43)
US 6089229A · Bathe · 2000 [cited by examiner]
US 6758214B2 · Fine et al. · 2004 [cited by applicant]
US 7025869B2 · Fine et al. · 2006 [cited by applicant]
US 7560076B2 · Rounbehler et al. · 2009 [cited by applicant]
US 7618594B2 · Rounbehler et al. · 2009 [cited by applicant]
US 7914743B2 · Fine et al. · 2011 [cited by applicant]
US 7947227B2 · Fine et al. · 2011 [cited by applicant]
US 8057742B2 · Rounbehler et al. · 2011 [cited by applicant]
US 8173072B2 · Fine et al. · 2012 [cited by applicant]
US 8268252B2 · Fuller et al. · 2012 [cited by applicant]
US 8607785B2 · Fine et al. · 2013 [cited by applicant]
US 8613958B2 · Fine · 2013 [cited by applicant]
US 8646445B2 · Fine et al. · 2014 [cited by applicant]
US 8701657B2 · Fine et al. · 2014 [cited by applicant]
US 8887720B2 · Fine et al. · 2014 [cited by applicant]
US 9279794B2 · Tolmie · 2016 [cited by examiner]
US 9982354B2 · Kim · 2018 [cited by applicant]
US 10213572B2 · Gellman et al. · 2019 [cited by applicant]
US 10780241B2 · Fine et al. · 2020 [cited by applicant]
US 10960168B2 · Fine et al. · 2021 [cited by applicant]
US 11000484B2 · Fine · 2021 [cited by applicant]
US 11154210B2 · Watts et al. · 2021 [cited by applicant]
US 11208326B1 · Fine et al. · 2021 [cited by applicant]
US 11243197B1 · Fine et al. · 2022 [cited by applicant]
US 20090314289A1 · Fine · 2009 [cited by examiner]
US 20100043789A1 · Fine · 2010 [cited by applicant]
US 20110240019A1 · Fine · 2011 [cited by examiner]
US 20120093948A1 · Fine et al. · 2012 [cited by applicant]
US 20120285449A1 · Fine et al. · 2012 [cited by applicant]
US 20140127081A1 · Fine et al. · 2014 [cited by applicant]
US 20140127330A1 · Fine et al. · 2014 [cited by applicant]
US 20150314101A1 · Acker · 2015 [cited by examiner]
US 20150320951A1 · Acker · 2015 [cited by examiner]
US 20150328429A1 · Acker · 2015 [cited by applicant]
US 20150335850A1 · Santhana et al. · 2015 [cited by applicant]
US 20160106946A1 · Gellman · 2016 [cited by examiner]
US 20160346498A1 · Tector et al. · 2016 [cited by applicant]
US 20170095634A1 · Miller · 2017 [cited by applicant]
US 20170165293A1 · Dasse et al. · 2017 [cited by applicant]
US 20170165294A1 · Dasse et al. · 2017 [cited by applicant]
US 20170165447A1 · Dasse et al. · 2017 [cited by applicant]
US 20170182088A1 · Dasse et al. · 2017 [cited by applicant]
US 20180243527A1 · Zapol · 2018 [cited by examiner]